Delcath Systems, Inc. (DCTH)

Market Cap	342.54M
Revenue (ttm)	79.60M
Net Income (ttm)	1.20M
Shares Out	35.31M
EPS (ttm)	0.03
PE Ratio	281.11
Forward PE	66.90
Dividend	n/a
Ex-Dividend Date	n/a

Volume	413,758
Open	9.60
Previous Close	9.64
Day's Range	9.55 - 9.95
52-Week Range	8.12 - 18.23
Beta	0.41
Analysts	Strong Buy
Price Target	22.60 (+132.99%)
Earnings Date	Nov 4, 2025

About DCTH

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1988
• Employees: 96
• Stock Exchange: NASDAQ
• Ticker Symbol: DCTH
• Website: https://www.delcath.com

Financial Performance

In 2024, Delcath Systems's revenue was $37.21 million, an increase of 1701.69% compared to the previous year's $2.07 million. Losses were -$26.39 million, -44.66% less than in 2023.

Analyst Summary

According to 5 analysts, the average rating for DCTH stock is "Strong Buy." The 12-month stock price target is $22.6, which is an increase of 132.99% from the latest price.

Price Target

$22.6

(132.99% upside)

Analyst Consensus: Strong Buy